Navigation Links
Selexis SA to Partner and Exhibit at BIO 2011 in Washington DC
Date:6/1/2011

.zerista.com/exhibitor/member/17326). For the exhibit hall schedule, visit: e.mybio.zerista.com/event/print

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a privately held biotechnology company dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (i.e. MAbs, growth factors, enzymes). The Company's SURE Cell Line Development™ Technology Platform is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. The technology platform also includes Selexis SUREtech Vectors™, Selexis SUREfection™ Transfection Methods, Selexis SUREvariant Screening™ and the proprietary Selexis SURE CHO-M Cell Line™.

For more information visit www.selexis.com

Contact:
Robert Meister
(602) 953-1716
robert.meister@selexis.com


'/>"/>
SOURCE Selexis SA
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome
2. Selexis SA Doubles Cell Line Development Laboratory Space in Geneva, Switzerland
3. Irvine Scientific and Selexis to Announce Results of Successful Collaboration
4. Selexis Launches Biosimilar Cell Line Development Program
5. Pfizer Inc. and PAREXEL International Corp. Sign Strategic Partnership Agreement to Advance Clinical Development
6. Local Partnership Addresses Lagging Scores and Interest in Science and Math Among Students
7. Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
8. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
9. Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research
10. Aperio Partners with Definiens to Market Definiens Tissue Studio for Advanced Image Analysis
11. John McKearn, Ph.D., Promoted to Managing Director of RiverVest Venture Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 Carahsoft and CDS ... January 23, 2014 at 2pm EST (11am PST), “Natural ... topic focuses on how technology can turn raw, heterogeneous ... for government agencies. The online webinar will last approximately ...
(Date:1/14/2014)... Jan. 14, 2014 As pet owners drew up their lists ... them wrote: "Take better care of my furry companion." Nowadays there ... and top-brand carrying cases to take the little canine or feline ... feel compelled to buy some pricey toys at the pet store. ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... Underscores Morphotek,s Commitment to the Development of Farletuzumab ... Specialty Development and Manufacturing SolutionsEXTON, Pa. and BASEL, ... of Eisai Corporation of North America, and Lonza ... executed a manufacturing services agreement to support the ...
... and biotech,companies are drawing on Singapore,s integrated network ... productivity, leverage academic,insights and diversify risks. Located at ... is representative of key Asian ethnic groups, Singapore ... and develop new solutions for,Asia and beyond. , ...
... signed an agreement-in-principle to ensure the valorization and the operation ... the Faculty of veterinary medicine in St-Hyacinthe, Quebec, Canada, for ... ... Laval, Quebec (PRWEB) May 18, 2009 -- Universite de ...
Cached Biology Technology:Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 2Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 3Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 4Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 2Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 3Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 4Pharma and Biotech Companies Plug into Singapore's Integrated Research Network 5
(Date:7/9/2014)... Emerging fungal pathogens pose a greater threat to ... declines of amphibians, bats, corals, bees and snakes. ... published in the prestigious journal Nature ... resistance to a deadly chytrid fungus implicated in ... is important because it is the basis of ...
(Date:7/9/2014)... 2014Biofuels derived from the oils produced by algae may ... achieve this goal, optimization of cost effective strategies for ... is needed. Sapphire Energy has developed an innovative solution ... cultivation systems, described in Industrial Biotechnology , a ... article is available on the Industrial Biotechnology ...
(Date:7/9/2014)... Genome Atlas (TCGA) Research Network have identified novel ... adenocarcinoma, the most common subtype of lung cancer. ... number of possible therapeutic targets for this disease ... with treatable mutations because many potent cancer drugs ... is jointly funded and managed by the National ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Controlling contamination in open algae ponds for biofuels 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3
... Hill, CA Bowman Design Group, an integrated marketing and ... marketing, is the first and only company in the ... the German exhibition and events industry association. Third party ... company met or exceeded goals set for nine criteria ...
... DIEGO At the Plenary Session of the American ... AAPS President Tony DeStefano, Ph. D. will present the ... the pharmaceutical sciences: AAPS Ligand Binding Assays ... Alison Joyce, B.S. (lead author); Sheldon Leung, Ph.D.; ...
... When determining the potential effects pesticides could pose ... Protection Agency, National Marine Fisheries Service (NMFS), and ... common scientific approach, says a new report from ... should use a risk assessment approach that addresses ...
Cached Biology News:Bowman Design Group is first US company awarded German FAMAB 'Sustainable Company' certification 2AAPS announces 2013 National Biotechnology Conference award winners 2Agencies should use common approach to evaluate risks pesticides pose to endangered species 2Agencies should use common approach to evaluate risks pesticides pose to endangered species 3
... commonly used as a fusion partner when ... GSTTag sequence has been reported to enhance ... solubility of its fusion partners. When expressed ... fusion proteins can be purified with immobilized ...
... is from the C-terminal end of the mouse retinoic acid receptor beta ... to 448 of RAR*. The sequence of PEP-005 is (amino to ... P - S - S - V - E - N - ... P - L - L - Q (The N-terminal cysteine has ...
... use of small interfering RNA (siRNA) molecules ... interference (RNAi) pathway have generated tremendous interest ... siRNA for experimental use can be synthesized ... then transfected into the target cells in ...
... is an automated hybridization system for the ... both the hybridization and post hybridization washing ... single instrument can process up to 12 ... has multi-protocol software, enabling the user to ...
Biology Products: